Publication: 4691

Publication: 4691

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial.

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: JAMA Oncol

Year:: 2025
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: Other-NOS
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 15

Parents:: 4510 4637
Children:: None

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:: Pfizer, Natera (CSC0218)
Grants:: U10CA180821, U10CA180882, U24CA196171, UG1CA189830, UG1CA233180, UG1CA233339; U10CA180863, CCS 707213 (CCTG); U10CA180794, U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG Oncology); U10CA180888, UG1CA233163 (SWOG), T32 CA009001 (Zhang)

Corr. Author:
Authors:: George Q Zhang Jeffrey A Meyerhardt Qian Shi Tyler Twombly Levi Pederson Chao Ma Juha P Väyrynen Melissa Zhao Yasutoshi Takashima Ardaman Shergill Pankaj Kumar Felix Couture Philip Kuebler Smitha Krishnamurthi Benjamin Tan Eileen M O'Reilly Marios Giannakis Shuji Ogino Adham Jurdi Shruti Sharma Alexey Aleshin Anthony F Shields Jonathan A Nowak

Networks:: HEARTLAND, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NY016, NY141, OH027

Study: CALGB-80702
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: